Острая декомпенсация сердечной недостаточности: влияние левосимендана и добутамина на клинико-гемодинамические показатели, почечную функцию и уровень мозгового натрийуретического
Диссертация
СКФ<30 мл/мин/1,73м) встречались у 8,3% больных. За период госпитализации острое повреждение почек, определенное как повышение уровня креатинина в динамике на 26,4 мкмоль/л и более, наблюдалось у 40,8% больных, причем чаще в группе, потребовавшей в последующем назначения инотропных препаратов (53,6%). Летальность в группе больных с острым повреждением почек была достоверно выше (30,4%), чем… Читать ещё >
Список литературы
- Андреев Д.А. Натрийуретические пептиды В-типа при сердечной недостаточности: диагностика, оценка прогноза и эффективности лечения. Лаб мед 2003−6.
- Беленков Ю.Н., В.Ю.Мареев, Ф. Т. Агеев НИИ кардиологии им. А. Л. Мясникова. Эпидемиологические исследования сердечной недостаточности: состояние вопроса ЖСН, ноябрь, т. 5 № 6 2004 г.
- Бритов А.Н. «Вопросы профилактики и лечения гипертонии на популяционном уровне». Клин. Мед.—1984−9:15−18.
- Гогин Е.Е. Гипертоническая болезнь. М. 1997:45−49
- Гургенян C.B., Адамян К. Г., Крищян Э. М. с соавт. Влияние гемодинамического и гормонального факторов на развитие гипертрофии левого желудочка у больных артериальной гипертонией. Кардиология 1996−7:46−51
- Доскиным В. А., Н. А. Лаврентьевой, В. Б. Шараем и М. П. Мирошниковым Тест САН — разновидность опросников состояний и настроений. Разработан сотрудниками 1 Московского медицинского института имени И. М. Сеченова в 1973 г.
- Дроздов В.Н. «Обмен мочевой кислоты у больных гипертонической болезнью с метаболическим синдромом «Автореферат диссертации на соискание ученой степени кандидата медицинских наук. Москва-1999.
- Елисеев О. М. Натрийуретические пептиды. Эволюция знаний Российский кардиологический научно-производственный комплекс Минздрава РФ, Москва.
- Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Ревишвили А. Ш. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал сердечная недостаточность Том 8 № 2 2006. С. 1−35
- Моисеев B.C., Кобалава Ж. Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечнососудистых заболеваний). Клин фармак тер 2002- 11(3): 16−8.
- Moiseyev V.S. et al. Safety and efficacy of a novel calcium sencitezer, Levosimendan, in patients with LVF due to an acute myocardial infarction. RUSSLAN. Eur Heart J 2002- 23: 1422−32.
- Моисеев B.C., Терещенко C.H., Павликова Е. П., Явелов И. С. Диагностика и лечение острой сердечной недостаточности. Рабочая группа по формированию рекомендаций ВНОК и ОССН, 2005. N. 20. № 2. — С. 208 -209.211
- Мухин H.A., Моисеев B.C., Кобалава Ж. Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив 2004- 6: 39−46
- Мухин H.A. Снижение скорости клубочковой фильтрации -общепопуляционный маркер неблагоприятного прогноза. Тер архив 2007- 6: 5−10.
- Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации (второй пересмотр). Кардиоваск тер профил 2008- 4 (Приложение).
- Сигитова О. Н. Хроническая болезнь почек и хроническая почечная недостаточность: современные подходы к терминологии, классификации и диагностике / О. II. Сигитова // Вестн. соврем, клин, медицины. 2008. — № 1.-С. 87
- Смирнов А.В., Добронравов В. А., Каюков И. Г. Проблема хронической болезни почек в современной медицине. Артер гиперт 2006- 12(3): 185−93.
- Смирнов А. В, И. Г. Каюков, В. А. Добронравов, А. Г. Кучер. Острое повреждение почек — новое понятие в нефрологии. Клиническая нефрология 1- 2009 С.11−15.
- Tavazzi L, Maggioni АР, Lucci D, et al: Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J 2006- 27:1207—1215
- Терещенко C.H., Демидова И. В. Почечная функция при хронической сердечной недостаточности у больных пожилого и старческого возраста. Сердце. 2002- 1-№ 5:251−256
- Томилина Н.А., Бигбов Б. Т. Эпидемиология хронической почечной недостаточности и новые подходы к классификации и оценке тяжести хронических прогрессирующих заболевания почек. Тер архив 2005- 6: 87−92.
- Фомин И.В., Беленков Ю. Н., Мареев В. Ю. и соавт. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации данные ЭПОХА-ХСН. Сердечная Недостаточность 2006. — т.7, № 3: 112−115.
- Ханина Н.Ю., А.А. Упницкий, Белоусов Ю. Б., Кафедра клинической фармакологии с курсом фармакокинетики ГОУ ВПО РГМУ, г. Москва Перспективные направления в лечении сердечной недостаточности Качественная клиническая практика 2006- 1:2−9.
- Шилов Е.Н., Фомин В. В., Швецов М. Ю. Хроническая болезнь почек. Тер архив 2007- 6: 75−8.
- Abbas S., Benjamin A., Ryblcki A., et al. Clinical Predictors of Heart Failure in Patients With First Acute Myocardial Infarction. Am Heart J 1999- 138: 1133−1139.
- Alderman MH: Serum Uric Acid As a Cardiovascular Risk Factor for Heart Disease. Current Hypertension Reports 2001, 3:184−189.
- Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS. A volumeindependent component to postdiuretic sodium retention in humans. J Am Soc Nephrol 1993−3:1878−83.
- Alvarez J., Taboada M., Rodriguez J. et al. Hemodynamic effects of levosimendan following cardiac surgery. Rev Esp Anestesiol Reanim 2005 Aug-Sep-52(7):389−94.
- Antila S., Eha J., Heinpalu M. et al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol. 1996- 49(6): 451−8.
- Baigent C, Landray MJ. Study of Heart and Renal Protection (SHARP). Kidney Int 2003- 63 (Suppl 84): S207−10.
- Bella J., Liu J., Roman M. et al. Cardiovascular features and prognosis of adults with renal dysfunction: the strong heart disease. J. Am. Coll. Cardiol., 2002, 39 (5), 440A.)
- Best P. Lennon R. Ting H. Et al. Even mild renal insufficiency is associated with increased mortality after coronary interventions. J. Am. Coll. Cardiol., 2001,37(2), 76 A.
- Binkley P.F., Nunziata E., Hatton P. S., Leier C.V. The positive inotropic agent levosimendan mediates increased cardiac output without progression of sympathovagal imbalance in patients with heart failure. Circulation 2000- 18 (suppl): 102.
- Boersma C, Atthobari J, Gansevoort RT, et al. Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making. Pharmacoeconomics 2006- 24(6): 523−35.
- Brosius FC III, Hostetter TH, Kelepouris E, et al. AHA Science advisory on detection of kidney disease in patients with or at increased risk of cardiovascular disease. Circulation 2006- 114: 1083−7.
- Cavana M, Pignataro C, Fraticelli A, Mebazaa A. The clinical experience with levosimendan in anesthesiology and in the intensive care unit. Ital Heart J 2003- 4 (Suppl 2): 61−4S.
- CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet, 1999, 353, 9−13.
- Cleland JG, Swedberg K, Follath F, et al: The EuroHeart Failure survey programme—A survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 2003- 24:442−463
- Cleland J.G., Takala A., Apajasalo et al. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail 2003 Jan-5(l):101−8.
- Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 200 713−49:675- 83.
- Cowie M. R., A. Mosterdft, D. A. Wood, J. W. Deckers, P. A. Poole-Wilson, G. C. Sutton and D. E. Grobbeef-The epidemiology of heart failure- European Heart Journal (1997) 18, 208−225
- Cowie M., Wood D., Coats A. et al. Incidece and aetiology of heart failure. A population-based study. Eur. Heart J. 1999, 20, 421−428.
- Dao Q., Krishnaswamy P., Kazanegra R. et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001−37:379−385.
- Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002−40:221−6.
- Dixon S. Grines C., Cox D. Creatinine clearance on admission predicts early and late death after primary angioplasty. J. Am. Coll. Cardiol., 2001, 37 (2), 361 A.)
- Evid Based Cardiovasc Med. 1998 Dec -2 (4): 113−4 16 379 864 Variation in use of invasive procedures in acute ischemic syndromes. S Kaul, J S Forrester Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Faivre V., Kaskos H., Callebert J. et al. Cardiac and Renal Effects of Levosimendan, Arginine Vasopressin, and Norepinephrine in Lipopolysaccharide-treated Rabbits. Anesthesiology 2005 Sep- 103(3):514−521.
- Fellstrom B, Zannad F, Schmieder R, et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005- 6:9.
- Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe lowoutput heart failure (the LIDO study): a randomised doubleblind trial. Lancet 2002- 360: 196−202.
- Follath F. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Ital Heart J. 2003 May-4 Suppl 2:34S-38S.
- Follath F., Franco F., Cardoso J.S. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol 2005 Sep 19−96(6A):80G-5G.
- Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003−4(Suppl. 7):S21-S30.
- Garcia Puig J, Ruilope LM: Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999, 17:869−872.
- Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005 Sep 19−96(6A):68G-73G.
- Gottdiener J., Brown J. Zoltic J. et al. Left ventricular hypertrophy in men with normal blood pressure: relation to exaggerated blood pressure response to exercise. Ann Inter. Med. 1990:112:3:161−166.
- Goldberg A, Hammerman H, Petcherski S, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J 2005- 150:330 -7.
- Goya Wannamethee S.: Serum Uric Acid Is Not an Independent Risk Factor for Coronary Heart Disease. Current Hypertension Reports 2001, 3:190 196.
- Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Task force for the diagnosis and treatment of chronic heart failure of the European Society of cardiology. Eur Heart J 2005−26:1115−1140.
- Gillum R. Epidemiology of heart failure in the United States. Am Heart J 1993- 126: 1042−47.
- Haikala H., Nissinen E., Etemadzadeh E. et all. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaction. J Cardiovasc Pharmacol
- Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 2002−62:237- 44.
- Han WK, Bonventre JV. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 2004−10:476−82.
- Heidenreich PA, Fonarow GC: Are registry hospitals different? A comparison of patients admitted to hospitals of a commercial heart failure registry with those from national and community cohorts. Am Heart J 2006- 152: 935−939
- Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004−66:1115−22.
- Hollenberg NK, Parving H-H, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007- 25: 1921−6.
- Hoste EA, Clennont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006- 10(3): R73.
- Howard PA, Dunn MI. Aggressive diuresis for severe heart failure in the elderly. Chest 2001- 119:807−10.
- Jose P, Skali H, Anavekar N, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006- 17:2886 -91.
- Kaheinen P., Polessello P., Levijoki J., Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium cannels. J Cardiovasc Pharmacol 2001- 37: 367−374.
- Kannel W. B. Prognostic implications of left ventricular hypertrophy in arterial hypertension. Arch. Mai. Coeur Vaiss 1990:83 Spec 4 :11−21
- Kannel W., Belanger A. Epidemiology of heart failure // Amer Heart J. -1991.-Vol. 121.-P. 951−957
- Kaplinsky E. Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc. Drugs Ther. 1994:8 Suppl 3:549−556
- Kirsch, B. Electron microscopy of the atrium of the heart. I. Guinea pig. Exp. Med. Surg., 1956, 14, 99.
- Kivikko M., Antila S., Eha J. et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin. Pharmacol 2002- 42:43−51.
- Kivikko M., Antila S., Eha J. et al. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002- 40: 465−471.
- Kivikko M., Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des 2005−11(4):435−55.
- Klapholz M, Maurer M, Lowe AM, et al: Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction. J Am Coll Cardiol 2004−43:1432−1438
- Kober L, Pedersen CT. Clinical characteristics and mortality of patients screend for entry into Trandolapril Cardiac Evaluation (TRACE) study. Am J Cardiol. 1995- 76: 1−5.
- Levy D. Clinical significance of left ventricular hypertrophy: insights from the Framingham Study. J. Cardiovasc. Pharmacol. 1991:17 Suppl 2:1−6
- Levey AS, Bosch JP, Lewis JB et al. A more accurate method toestimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999- 130:461−470.
- Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998- 19: 660−668
- Littlewood KJ, Greiner W, Baum D, Zoellner Y. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC Nephrology 2007- 8: 9doi: 10.1186/1471 -23 69−8-9.
- Lubien E., DeMaria A., Krishnaswamy K. Utility of B-natriuretic peptide in diagnosing diastolic disfunction. Circulation 2002- 105:595—601.
- Lukowucz T., Fischer M., Hense H. et al. BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy. Eur J Heart Failure 2005−7:525−531.
- Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002−347:161−167.
- Malik M., Balchvarov V. Measurement, interpretation and clinical potential of QT dispersion. JACC 2000- 36: 1749−1766.
- Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004- 22: 1613−22.
- Maytin M, Colucci W.S. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005 Sep 19−96(6A):26G-31G.
- McCullough P., Nowak R., McCord J. et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure. Circulation 2002−106:416−420.
- McCullough PA. Contrast induced nephropathy. J Am Coll Cardiol 2008−51:1419−28.
- Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve autcomes in acute kidney injury. Crit Care 2007- 11(2):R31.
- MERIT-HF study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999, 353. 2001−2007.
- Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Estimated Glomerular Filtration Rate, Inflammation, and Cardiovascular Events After an Acute Coronary Syndrome. Am Heart J 2008- 155(4): 725−31.
- Mihai Gheorghiade, Faiez Zannad, George Sopko, Liviu Klein. Acute Heart Failure Syndromes: Current State and Framework for Future Research. Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX. 72 514
- Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003−14:2534−43.
- Morelli A., De Castro S., Teboul J.L. et all. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005 May-31(5):638−44.
- Morisky DE, Greem LW, Levine DM, Concurrent and predictive validity of self-reported measure of medical adherence, Med Care 1986- 24: 67−73,
- Morita E., Yasue H., Yoshimura M. Increased plasma levels of brain natriuretic peptide in patient with acute myocardial infarction. Circulation 1993−88:82−91.
- National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002- 39(Suppl 1): S1−266.
- National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 2003- 41 (Suppl 4): Sl-92.
- National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004- 43 (5 Suppl 1): S1−290.
- National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006- 47(Suppl 3): S1−146.
- National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007: 49 (Suppl 2): S1−180.
- Ndrepepa, G, Braun, S, Niemoller, K, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation 2005- 112:2102.
- Nguyen MT, Ross GF, Dent CL, Devarajan P. Early prediction of acute renal injury using urinary proteomics. Am J Nephrol 2005−25: 318−26.
- Nguyen HB, Losey T, Rasmussen J, et al. Interrater reliability of cardiac output measurements by transcutaneous Doppler ultrasound: Implications for noninvasive hemodynamic monitoring in the ED. Am J Emerg Med 2006−24:828 -35.
- Nicklas J.M., Monsur J.C., Bleske B.E. Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am J Cardiol 1999- 83: 12(1)-15(1).
- Nicol E, Fittall B, Roughton M, et al: National Health Service Heart Failure Survey— A survey of acute heart failure admissions in England, Wales and Northern Ireland. Heart 2007- In Press
- Nieminen M., Akkila J., Hasenfuss G. et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. JACC 2000- 36: 1903−1912.
- Nieminenl M.S., Brutsaert D., Dickstein K., et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006- 27: 2725−2736.
- Opdam HI, Wan L, Bellomo R. A pilot assessment of the FloTrac cardiac output monitoring system. Intensive Care Med 2007−33: 344−9.
- Owais Dar, MB ChB, MRCP- Martin R. Cowie, MD, MSc, FRCP
- Scientific Reviews. Acute heart failure in the intensive care unit: Epidemiology- Crit Care Med 2008 Vol. 36, No. 1 Suppl. S3- S8
- Papp Z., Csapo K., Pollesello P. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005 Spring- 23 (l):71−98.
- Parissis J.T., Panou F., Farmakis D. et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005 Aug l-96(3):423−6.
- Parving H-H, Persson F, Lewis J, et al. for the AVOID Study Investigators. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med 2008- 358:243 -46.
- Peacock IV W.F., De Marco T., Fonarow G.C. et al. Cardiac Troponin and Outcome in Acute Heart Failure. N Engl J Med. May 15, 2008−358:2117−26.
- Poder P., Eha J., Antila S. et al. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc Drugs Ther 2003 Sep-Nov- 17(5−6):451−8.
- Poder P., Eha J., Sundberg S. et al. Pharmacodynamics and Pharmacokinetics of Oral Levosimendan and Its Metabolites in Patients With Severe Congestive Heart Failure: A Dosing Interval Study. J Clin Pharmacol October 1,2004- 44(10): 1143 1150.
- Remme W.J., and K. Swedberg (Chairpersons), Chronic Heart Failure European Heart Journal 2001- 22: 1527−1560
- REVIVE-2: Levosimendan improves five-day clinical status in acute HF. Сообщение подготовил Stiles S. www.theHeart.org ORION Abbott Lab. № UA/1812/01/01 от 15.07.2009 до 15.07.2014
- Ronco С, Ricci Z, Brendolan A, Bellomo R, Bedogni F. Ultrafiltration in patients with hypervolemia and congestive heart failure. Blood Purif 2004−22:150−63.
- Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007- 115: e69−171.
- Rudiger A, Harjola V-P, Muller A, et al: Acute heart failure: Clinical presentation, one-year mortality and prognostic factors. Eur J Heart Fail 2005- 7:662−670
- Ruilope LM, Garcia-Puig J.: Hyperuricemia and Renal Function. Current Hypertension Reports 2001, 3:197−202.
- Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for imnproving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006- 17: 2006—16.
- Shionoria B.N.P. Quantative immonoradiometric assay kit for the determination of human brain (B-type) natriuretic peptide in plasma product insert. Osaka (Japan): Shionogi and Co LTD-2002
- Siirila-Waris K., Suojaranta-Ylinen R., Harjola V.P. Levosimendan in cardiac surgery. J Cardiothorac Vase Anesth 2005 Jun-19(3):345−9.
- Soufer R, Wohlgelernter D, Vita NA et al. Intact systolic left ventricular function in clinical congestive heart failure. // Am J Cardiol, 1985- 55: 1032−6.
- Spirito P, Maron BJ, Bonow RO. Noninvasiv assessment of ventricular diastolic function: comparative analysis of Doppler echocardiographic andradionuclide angiographic techniques. // J Am Coll Cardiol, 1986−7:518−26.
- Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P. Differential gene expression following early renal ischemia/reperfusion. Kidney Int 2003−63:1714 —24.
- Sutton GC. Epidemiologic aspects of heart failure.// Am Heart J 1990- 120: 1538−40/
- Toivonen L., Viitasalo M., Sundberg S. et al. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 2000- 35: 664 669.
- TriageR BNP Test product insert., San Diego CA: Biosite Diagnostics Inc 2000.
- Ukkonen H., Saraste M, Akkila J. et al. Miocardial efficiency during levosimendan infusion in congestive heart failure. Clinical Pharmacology and Terapeutics 2000- 68: 522−531.
- Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006−290:F517−29.
- VandeVoorde RG, Katlman TI, Ma Q, et al. Serum NGAL and cystatin C as predictive biomarkers for acute kidney injury. J Am Soc Nephrol 2006−17:404A.
- Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007−50(2): 169−80.
- Wanner C, Krane V, Marz W, et al. Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. N Engl J Med 2005- 353: 238-^8.
- Yorgun H, Deniz A, Aytemir K. Cardiogenic shock secondary to combination of diltiazem and Sotalol. Intern Med J 2008−38:221−2. 28.
- Zannad F, Mebazaa A, Julliere Y, et al: Clinical profile, contemporary management and 1 year mortality in patients with severe acute heart failure syndrome: The EFICA study. Eur J Heart Fail 2006- 8:697−705
- Zobel C., Reuter H., Schwinger R.H. Treatment of cardiogenic shock with the Ca2+ sensitizer levosimendan. Med Klin (Munich) 2004 Dec 15−99(12):742−6.